1. Home
  2. AIFC vs PMN Comparison

AIFC vs PMN Comparison

Compare AIFC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIFC

AI Financial Corporation Common Stock

N/A

Current Price

$0.16

Market Cap

78.4M

Sector

Finance

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$3.31

Market Cap

84.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIFC
PMN
Founded
1976
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.4M
84.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
AIFC
PMN
Price
$0.16
$3.31
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $42.01
AVG Volume (30 Days)
★ 745.3K
367.4K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $12,532,000.00
N/A
Revenue This Year
$43.90
N/A
Revenue Next Year
$43.25
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.29
52 Week High
$0.72
$27.40

Technical Indicators

Market Signals
Indicator
AIFC
PMN
Relative Strength Index (RSI) 24.56 30.16
Support Level $0.16 $2.78
Resistance Level $0.63 $15.05
Average True Range (ATR) 0.03 1.18
MACD -0.00 -0.11
Stochastic Oscillator 4.18 5.79

Price Performance

Historical Comparison
AIFC
PMN

About AIFC AI Financial Corporation Common Stock

AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: